PTPRC and neoplasm: To this end, SCC VII tumor-bearing mice were treated with s.c. Mut_48 + polyI:C mixtures and/or i.p. anti-PD-1 at day 10 following tumor inoculation, and CD45+ cells were purified from TIL, splenocyte, and tumor-draining Ig LN fractions at the day 17 effector phase and processed for FACS.